

Simon R Johnson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7103009/publications.pdf>

Version: 2024-02-01

102
papers

6,742
citations

109264

35
h-index

62565

80
g-index

104
all docs

104
docs citations

104
times ranked

5745
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease monitoring using lung function trajectory in lymphangioleiomyomatosis: assessment in two national cohorts. <i>Thorax</i> , 2023, 78, 61-68.	2.7	3
2	Human bronchial epithelial cells from patients with asthma have an altered gene expression profile. <i>ERJ Open Research</i> , 2022, 8, 00625-2021.	1.1	2
3	Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling. <i>European Respiratory Journal</i> , 2022, 60, 2004361.	3.1	10
4	Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 936-948.	2.5	11
5	Cross talk between LAM cells and fibroblasts may influence alveolar epithelial cell behavior in lymphangioleiomyomatosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 322, L283-L293.	1.3	6
6	A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant. <i>Respiratory Medicine</i> , 2022, 195, 106779.	1.3	1
7	COVID-19 in Lymphangioleiomyomatosis. <i>Chest</i> , 2022, 161, 1589-1593.	0.4	5
8	Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 431-444.	2.5	11
9	Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13929.	3.3	6
10	Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1313-1327.	5.2	67
11	Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). <i>BMJ Open Respiratory Research</i> , 2021, 8, e001049.	1.2	28
12	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. <i>Pediatric Neurology</i> , 2021, 123, 50-66.	1.0	230
13	Mechanisms of Lung Cyst Formation. <i>Respiratory Medicine</i> , 2021, , 21-42.	0.1	0
14	Phenotypic and functional translation of IL33 genetics in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 144-157.	1.5	29
15	Machine learning can predict disease manifestations and outcomes in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2021, 57, 2003036.	3.1	6
16	Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts. <i>Thorax</i> , 2020, 75, 904-907.	2.7	18
17	Pneumothorax and the biology of Birt-Hogg-Dub� syndrome. <i>Thorax</i> , 2020, 75, 442-443.	2.7	2
18	Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis. <i>Thorax</i> , 2020, 75, 679-688.	2.7	9

#	ARTICLE	IF	CITATIONS
19	Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 215-226.	1.3	14
20	Phenotypic and functional translation of IL1RL1 locus polymorphisms in lung tissue and asthmatic airway epithelium. <i>JCI Insight</i> , 2020, 5, .	2.3	26
21	Airway epithelial cell isolation techniques affect DNA methylation profiles with consequences for analysis of asthma related perturbations to DNA methylation. <i>Scientific Reports</i> , 2019, 9, 14409.	1.6	11
22	Accelerated ¹⁹ F-MRI Detection of Matrix Metalloproteinase-2/-9 through Responsive Deactivation of Paramagnetic Relaxation Enhancement. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-13.	0.4	5
23	Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use. <i>Thorax</i> , 2019, 74, 999-1002.	2.7	11
24	Tuberous Sclerosis Complex (TSC): Expert Recommendations for Provision of Coordinated Care. <i>Frontiers in Neurology</i> , 2019, 10, 1116.	1.1	11
25	Reply to Yanagisawa: Treatment of Pulmonary Lymphangioleiomyomatosis during Pregnancy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1507-1508.	2.5	3
26	Extracellular Matrix Cross-Linking Enhances Fibroblast Growth and Protects against Matrix Proteolysis in Lung Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 594-603.	1.4	111
27	Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. <i>Thorax</i> , 2018, 73, 369-375.	2.7	65
28	Air travel and incidence of pneumothorax in lymphangioleiomyomatosis. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 222.	1.2	21
29	TAILS proteomics reveals dynamic changes in airway proteolysis controlling protease activity and innate immunity during COPD exacerbations. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 315, L1003-L1014.	1.3	20
30	A theoretical model of inflammation- and mechanotransduction-driven asthmatic airway remodelling. <i>Biomechanics and Modeling in Mechanobiology</i> , 2018, 17, 1451-1470.	1.4	19
31	The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2018, 52, 1800951.	3.1	13
32	Cathepsin K in Lymphangioleiomyomatosis. <i>American Journal of Pathology</i> , 2017, 187, 1750-1762.	1.9	23
33	Reply: The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 660-661.	2.5	0
34	Matrix Metalloproteinase-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1000-1009.	2.5	55
35	Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1337-1348.	2.5	159
36	Lymphangioleiomyomatosis. <i>Clinics in Chest Medicine</i> , 2016, 37, 389-403.	0.8	94

#	ARTICLE	IF	CITATIONS
37	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangiomyomatosis Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 748-761.	2.5	236
38	The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the Clinical Practice Research Datalink. <i>Journal of Medical Economics</i> , 2016, 19, 1087-1098.	1.0	21
39	Study of breast cancer incidence in patients of lymphangiomyomatosis. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 195-201.	1.1	9
40	The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: A retrospective cohort study in the Clinical Practice Research Datalink (CPRD). <i>European Journal of Paediatric Neurology</i> , 2016, 20, 296-308.	0.7	56
41	Untangling the protease web in COPD: metalloproteinases in the silent zone. <i>Thorax</i> , 2016, 71, 105-106.	2.7	8
42	Matrix metalloproteinases -8 and -9 in the Airways, Blood and Urine During Exacerbations of COPD. COPD: <i>Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 26-34.	0.7	18
43	Secretory leukocyte protease inhibitor gene deletion alters bleomycin-induced lung injury, but not development of pulmonary fibrosis. <i>Laboratory Investigation</i> , 2016, 96, 623-631.	1.7	23
44	Accelerated extracellular matrix turnover during exacerbations of COPD. <i>Respiratory Research</i> , 2015, 16, 69.	1.4	78
45	Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. <i>International Journal of COPD</i> , 2015, 10, 211.	0.9	22
46	A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangiomyomatosis in a national clinical centre. <i>Thorax</i> , 2015, 70, 1202-1204.	2.7	9
47	Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders. <i>Clinical Biochemistry</i> , 2015, 48, 1083-1088.	0.8	28
48	Wild Type Mesenchymal Cells Contribute to the Lung Pathology of Lymphangiomyomatosis. <i>PLoS ONE</i> , 2015, 10, e0126025.	1.1	32
49	Lymphangiomyomatosis. , 2015, , 271-283.		0
50	The Role of Inflammation Resolution Speed in Airway Smooth Muscle Mass Accumulation in Asthma: Insight from a Theoretical Model. <i>PLoS ONE</i> , 2014, 9, e90162.	1.1	21
51	Extra-Cellular Matrix Proteins Induce Matrix Metalloproteinase-1 (MMP-1) Activity and Increase Airway Smooth Muscle Contraction in Asthma. <i>PLoS ONE</i> , 2014, 9, e90565.	1.1	35
52	Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. <i>Thorax</i> , 2014, 69, 207-215.	2.7	106
53	A 2-year randomised placebo-controlled trial of doxycycline for lymphangiomyomatosis. <i>European Respiratory Journal</i> , 2014, 43, 1114-1123.	3.1	60
54	The Role of Extracellular Matrix Quality in Pulmonary Fibrosis. <i>Respiration</i> , 2014, 88, 487-499.	1.2	36

#	ARTICLE	IF	CITATIONS
55	Natural history of angiomyolipoma in lymphangiomyomatosis: implications for screening and surveillance. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 151.	1.2	30
56	Doxycycline in lymphangiomyomatosis: not all questions are answered. <i>European Respiratory Journal</i> , 2014, 43, 1538-1538.	3.1	3
57	Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 243-254.	1.0	1,185
58	Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. <i>Pediatric Neurology</i> , 2013, 49, 255-265.	1.0	693
59	In search of the fibrotic epithelial cell: opportunities for a collaborative network. <i>Thorax</i> , 2012, 67, 179-182.	2.7	16
60	Interstitial lung disease following certolizumab pegol. <i>Rheumatology</i> , 2012, 51, 578-580.	0.9	34
61	Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. <i>Respiratory Medicine</i> , 2012, 106, 759-768.	1.3	25
62	Rare Diffuse Interstitial Lung Diseases. , 2012, , 667-675.		0
63	Clinical utility of diagnostic guidelines and putative biomarkers in lymphangiomyomatosis. <i>Respiratory Research</i> , 2012, 13, 34.	1.4	50
64	<sc>CCR</sc>3 induced <sc>MAPK</sc> activation protects against staurosporine induced <sc>DNA</sc> fragmentation but not apoptosis in airway smooth muscle cells. <i>Clinical and Experimental Allergy</i> , 2012, 42, 1040-1050.	1.4	8
65	Discoidin domain receptor 1 regulates bronchial epithelial repair and matrix metalloproteinase production. <i>European Respiratory Journal</i> , 2011, 37, 1482-1493.	3.1	35
66	Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangiomyomatosis: A Phase 2 Trial. <i>Clinical Cancer Research</i> , 2011, 17, 4071-4081.	3.2	278
67	Use of variability in national and regional data to estimate the prevalence of lymphangiomyomatosis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 971-979.	0.2	121
68	Matrix metalloproteinase-12 (MMP-12) SNP affects MMP activity, lung macrophage infiltration and protects against emphysema in COPD. <i>Thorax</i> , 2011, 66, 970-976.	2.7	36
69	Fungal Recognition Enhances Mannose Receptor Shedding through Dectin-1 Engagement. <i>Journal of Biological Chemistry</i> , 2011, 286, 7822-7829.	1.6	53
70	Association of MMP - 12 polymorphisms with severe and very severe COPD: A case control study of MMPs - 1, 9 and 12 in a European population. <i>BMC Medical Genetics</i> , 2010, 11, 7.	2.1	70
71	Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2010, 299, L393-L400.	1.3	44
72	Role of the CXCR4/CXCL12 Axis in Lymphangiomyomatosis and Angiomyolipoma. <i>Journal of Immunology</i> , 2010, 185, 1812-1821.	0.4	18

#	ARTICLE	IF	CITATIONS
73	Living with lymphangioleiomyomatosis. <i>BMJ: British Medical Journal</i> , 2010, 340, c848-c848.	2.4	5
74	The International LAM Registry: A Component of an Innovative Web-Based Clinician, Researcher, and Patient-Driven Rare Disease Research Platform. <i>Lymphatic Research and Biology</i> , 2010, 8, 81-87.	0.5	14
75	The ERS guidelines for LAM: Trying a rationale approach to a rare disease. <i>Respiratory Medicine</i> , 2010, 104, S33-S41.	1.3	23
76	European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2010, 35, 14-26.	3.1	468
77	Analysis of the oestrogen response in an angiomyolipoma derived xenograft model. <i>Endocrine-Related Cancer</i> , 2009, 16, 59-72.	1.6	21
78	Use of a three-dimensional cell culture model to study airway smooth muscle-mast cell interactions in airway remodeling. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 296, L1059-L1066.	1.3	34
79	Tissue and matrix influences on airway smooth muscle function. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 379-387.	1.1	40
80	Pregnancy experiences among women with lymphangioleiomyomatosis. <i>Respiratory Medicine</i> , 2009, 103, 766-772.	1.3	70
81	MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. <i>Respiratory Medicine</i> , 2008, 102, 845-851.	1.3	33
82	Sirolimus Therapy in Tuberous Sclerosis or Sporadic Lymphangioleiomyomatosis. <i>New England Journal of Medicine</i> , 2008, 358, 200-203.	13.9	208
83	Air travel in women with lymphangioleiomyomatosis. <i>Thorax</i> , 2007, 62, 176-180.	2.7	45
84	Subcellular distribution of the TSC2 gene product tuberin in human airway smooth muscle cells is driven by multiple localization sequences and is cell-cycle dependent. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2007, 292, L258-L266.	1.3	10
85	Management of rare diseases in respiratory medicine. <i>Clinical Medicine</i> , 2007, 7, 447-448.	0.8	0
86	Lymphangioleiomyomatosis. , 2007, , 275-284.		2
87	Lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2006, 27, 1056-1065.	3.1	211
88	TIMP-1 in asthma: guilty by association. <i>Thorax</i> , 2005, 60, 617-618.	2.7	4
89	Emerging clinical picture of lymphangioleiomyomatosis. <i>Thorax</i> , 2005, 60, 875-879.	2.7	77
90	Introduction. <i>Chronic Respiratory Disease</i> , 2005, 2, 73-73.	1.0	0

#	ARTICLE	IF	CITATIONS
91	Pulmonary artery aneurysm and tuberous sclerosis. <i>Thorax</i> , 2004, 59, 86-86.	2.7	16
92	Survival and disease progression in UK patients with lymphangiomyomatosis. <i>Thorax</i> , 2004, 59, 800-803.	2.7	137
93	Matrix metalloproteinase expression and activity in human airway smooth muscle cells. <i>British Journal of Pharmacology</i> , 2004, 142, 1318-1324.	2.7	62
94	Lymphangiomyomatosis: a case-control study of perinatal and early life events. <i>Thorax</i> , 2003, 58, 979-982.	2.7	2
95	Lymphangiomyomatosis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2002, 23, 085-092.	0.8	36
96	The TSC-2 product tuberlin is expressed in lymphangiomyomatosis and angiomyolipoma. <i>Histopathology</i> , 2002, 40, 458-463.	1.6	16
97	An assay to evaluate the long term effects of inflammatory mediators on airway smooth muscle: evidence that TNF α up-regulates 5-HT _{2A} mediated contraction. <i>British Journal of Pharmacology</i> , 2002, 137, 943-944.	2.7	3
98	Effects of Growth Factors and Extracellular Matrix on Survival of Human Airway Smooth Muscle Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 25, 569-576.	1.4	134
99	Clinical experience of lymphangiomyomatosis in the UK. <i>Thorax</i> , 2000, 55, 1052-1057.	2.7	215
100	Autocrine production of matrix metalloproteinase-2 is required for human airway smooth muscle proliferation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1999, 277, L1109-L1117.	1.3	57
101	Synthetic functions of airway smooth muscle in asthma. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 288-292.	4.0	98
102	Synthetic functions of airway smooth muscle in asthma. <i>Trends in Pharmacological Sciences</i> , 1997, 18, 288-292.	4.0	95